An observational study in B-cell Mediated Autoimmune Disorders, sponsored by TG Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 62 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by TG Therapeutics, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Any participants receiving azer-cel in TG-Azercel -101 study will be enrolled in this LTFU study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Citeria:
1. No unique exclusion criteria apply to this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received azer-cel in TG-Azercel -101 study will be followed-up for a total of 15 years until withdrawal of consent, lost to follow-up, or until death.
Other: No Intervention
No Intervention
Number of Participants With Clinically Significant CEI
Time frame: Up to 15 years
Number of Participants With Clinically Significant CEI Based on Severity
Time frame: Up to 15 years
Duration of Clinically Significant CEI
Time frame: Up to 15 years
Time to Onset of Clinically Significant CEI
Time frame: Up to 15 years
Number of Participants With CEI and all Serious Adverse Events (SAEs)
Time frame: Up to 15 years
Duration of Disease Response Measured by Expanded Disability Status Scale (EDSS) Scores
The EDSS is a standardized tool used to measure disability in participants with multiple sclerosis (MS). The EDSS scores range from 0 to 10, based on the severity of disability. Higher score indicates severity of disability.
Time frame: Up to 15 years
Duration of Disease Response Measured by Number of MS Relapses
Time frame: Up to 15 years
Duration of Disease Response Based on Number of T2 Lesions and Gd-enhancing T1 Lesions
Time frame: Up to 15 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2027; primary completion for Dec 2039, 151 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.